Profile data is unavailable for this security.
About the company
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.
- Revenue in USD (TTM)0.00
- Net income in USD-80.33m
- Incorporated2020
- Employees64.00
- LocationPepGen Inc245 Main St, 2nd FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (703) 456-8000
- Fax+1 (302) 655-5049
- Websitehttps://pepgen.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Voyager Therapeutics Inc | 119.04m | -3.04m | 440.59m | 162.00 | -- | 1.29 | 290.24 | 3.70 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 442.22m | 19.00 | -- | 4.48 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 443.91m | 127.00 | -- | 5.59 | -- | 88.78 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
| Korro Bio Inc | 0.00 | -81.19m | 445.85m | 94.00 | -- | 2.55 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Verve Therapeutics Inc | 16.05m | -196.83m | 447.54m | 255.00 | -- | 0.7662 | -- | 27.89 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Cartesian Therapeutics Inc | 25.91m | -254.87m | 453.09m | 38.00 | -- | -- | -- | 17.49 | -48.02 | -48.02 | 4.94 | -21.18 | 0.1077 | -- | 5.86 | 681,736.80 | -106.00 | -43.66 | -122.03 | -66.84 | -- | -- | -983.83 | -136.35 | -- | -0.5249 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Ocugen Inc | 7.05m | -58.50m | 458.04m | 65.00 | -- | 15.14 | -- | 64.97 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Tscan Therapeutics Inc | 14.81m | -96.80m | 459.91m | 161.00 | -- | 3.39 | -- | 31.05 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Nkarta Inc | 0.00 | -116.20m | 460.86m | 150.00 | -- | 0.9728 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Fulcrum Therapeutics Inc | 2.51m | -99.43m | 461.18m | 76.00 | -- | 2.16 | -- | 183.74 | -1.61 | -1.61 | 0.0406 | 3.44 | 0.0091 | -- | 2.14 | 33,026.32 | -35.91 | -50.55 | -37.62 | -55.91 | -- | -- | -3,961.20 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| PepGen Inc | 0.00 | -80.33m | 461.62m | 64.00 | -- | 2.58 | -- | -- | -3.25 | -3.25 | 0.00 | 5.53 | 0.00 | -- | -- | 0.00 | -39.37 | -- | -42.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Applied Therapeutics Inc | -477.00k | -193.56m | 461.64m | 26.00 | -- | 6.86 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 476.31m | 118.00 | -- | 4.41 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| Larimar Therapeutics Inc | 0.00 | -45.08m | 476.60m | 42.00 | -- | 2.06 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| Editas Medicine Inc | 69.41m | -166.13m | 479.45m | 265.00 | -- | 1.63 | -- | 6.91 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Data as of May 23 2024. Currency figures normalised to PepGen Inc's reporting currency: US Dollar USD
63.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 10.69m | 33.00% |
| Suvretta Capital Management LLCas of 31 Mar 2024 | 1.52m | 4.70% |
| Viking Global Investors LPas of 31 Mar 2024 | 1.48m | 4.58% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 1.41m | 4.36% |
| Adage Capital Management LPas of 31 Mar 2024 | 1.33m | 4.12% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.17m | 3.60% |
| Laurion Capital Management LPas of 31 Mar 2024 | 841.43k | 2.60% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 836.47k | 2.58% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 726.48k | 2.24% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 458.64k | 1.42% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
